Fulcrum Therapeutics (FULC) Shares Outstanding (Diluted Average) (2020 - 2026)
Fulcrum Therapeutics (FULC) reported Shares Outstanding (Diluted Average) of $76.2 million for Q1 2026, up 21.98% year-over-year from $62.5 million in Q1 2025, and up 120198.32% quarter-over-quarter from $63355.0 in Q4 2025.
Fulcrum Therapeutics (FULC) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $76.2 million in Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $76.2 million, up 21.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.2 million (up 21.98% YoY), and the FY2025 annual result was $63355.0, up 2.21% from the prior year.
- Shares Outstanding (Diluted Average) improved to $76.2 million in Q1 2026 per FULC's latest filing, from $63355.0 in the prior quarter.
- Over five years, Shares Outstanding (Diluted Average) peaked at $76.2 million in Q1 2026 and troughed at $40644.0 in Q1 2022.
- A 5-year average of $34.0 million and a median of $61.8 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Diluted Average) soared 151474.76% in 2023, then retreated 1.85% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $44991.0 in 2022, then surged by 36.27% to $61310.0 in 2023, then advanced by 1.1% to $61984.0 in 2024, then grew by 2.21% to $63355.0 in 2025, then jumped by 120198.32% to $76.2 million in 2026.
- Business Quant data shows FULC's Shares Outstanding (Diluted Average) at $76.2 million in Q1 2026, $63355.0 in Q4 2025, and $62.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 92.44 Mn |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | 76.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76.22 Mn |
| Dec 31, 2025 | 63,355.00 |
| Sep 30, 2025 | 62.60 Mn |
| Jun 30, 2025 | 62.51 Mn |
| Mar 31, 2025 | 62.48 Mn |
| Dec 31, 2024 | 61,984.00 |
| Sep 30, 2024 | 63.69 Mn |
| Jun 30, 2024 | 63.68 Mn |
| Mar 31, 2024 | 61.98 Mn |
| Dec 31, 2023 | 61,310.00 |
| Sep 30, 2023 | 61.82 Mn |
| Jun 30, 2023 | 61.79 Mn |
| Mar 31, 2023 | 59,722.00 |
| Dec 31, 2022 | 44,991.00 |
| Sep 30, 2022 | 46,213.00 |
| Jun 30, 2022 | 40,768.00 |
| Mar 31, 2022 | 40,644.00 |
| Dec 31, 2021 | 35,361.00 |
| Sep 30, 2021 | 33,603.00 |
| Jun 30, 2021 | 32,636.00 |